These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14687450)

  • 21. Disintegration of sublingual tablets: proposal for a validated test method and acceptance criterion.
    Weda M; van Riet-Nales DA; van Aalst P; de Kaste D; Lekkerkerker JF
    Pharmeur Sci Notes; 2006 Dec; 2006(2):41-4. PubMed ID: 17691213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alendronate (Fosamax) and risedronate (Actonel) revisited.
    Med Lett Drugs Ther; 2005 Apr; 47(1207):33-5. PubMed ID: 15843782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International harmonization of generic drugs: in vitro dissolution tests for Japanese and American generic tablets.
    Otsuka M; Tomita H; Otsuka K; Kamae I; Jorgenson JA
    Biomed Mater Eng; 2006; 16(2):129-35. PubMed ID: 16477121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of DNA damage in postmenopausal women under osteoporosis therapy.
    Bayram M; Soyer C; Kadioglu E; Sardas S
    Eur J Obstet Gynecol Reprod Biol; 2006 Aug; 127(2):227-30. PubMed ID: 16504368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers.
    Wilding IR; Clark D; Wray H; Alderman J; Muirhead N; Sikes CR
    J Clin Pharmacol; 2005 Jan; 45(1):101-5. PubMed ID: 15601811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When do differences in dissolution profiles predict clinical problems?
    Ngo SN
    J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660
    [No Abstract]   [Full Text] [Related]  

  • 29. Alendronate-associated esophageal injury: pathologic and endoscopic features.
    Abraham SC; Cruz-Correa M; Lee LA; Yardley JH; Wu TT
    Mod Pathol; 1999 Dec; 12(12):1152-7. PubMed ID: 10619269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
    Strauch S; Jantratid E; Dressman JB
    J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
    Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
    Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin.
    Ahmed IS; Aboul-Einien MH
    Eur J Pharm Sci; 2007 Sep; 32(1):58-68. PubMed ID: 17628451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro and in vivo biopharmaceutical evaluation of lorazepam commercial tablets].
    Giannone I; Musumeci T; Pecora TM; Puglisi G
    Clin Ter; 2005; 156(5):197-201. PubMed ID: 16382968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the quality of four Mexican drug products containing sodium naproxen.
    Hernández-Abad VJ; Castañeda-Hernández G; García-Jiménez S; Marroquín-Segura R; Sánchez-González E
    J Clin Pharm Ther; 2008 Jun; 33(3):237-42. PubMed ID: 18452410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lot-to-lot variation in dissolution of tolbutamide tablets.
    Ayres JW
    Am J Hosp Pharm; 1980 Oct; 37(10):1329-32. PubMed ID: 7424928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An investigation of the disintegration of tablets in biorelevant media.
    Anwar S; Fell JT; Dickinson PA
    Int J Pharm; 2005 Feb; 290(1-2):121-7. PubMed ID: 15664137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphism in generic drug product development.
    Snider DA; Addicks W; Owens W
    Adv Drug Deliv Rev; 2004 Feb; 56(3):391-5. PubMed ID: 14962588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.